Table 3.
Complications, treatments, and outcomes in patients with and without Wuhan exposure history
| Variable | Exposure group (n=393) | Control group (n=395) | P value |
| Complication | |||
| Acute respiratory distress syndrome | 31 (7.89%) | 27 (6.84%) | 0.588 |
| Septic shock | 1 (0.25%) | 1 (0.25%) | 1.000 |
| Liver function abnormality | 39 (9.92%) | 43 (10.89%) | 0.727 |
| Acute kidney injury | 6 (1.53%) | 7 (1.77%) | 1.000 |
| Treatment | |||
| Anti-coronavirus treatment | 326 (82.95%) | 342 (86.58%) | 0.166 |
| Timing from onset of illness to antiviral therapy (d) | 3 (1–5) | 4 (1–7) | <0.001 |
| Antivirus regimen | |||
| Interferon-α+lopinavir/ritonavir+arbidol | 94 (23.92%) | 141 (35.70%) | <0.001 |
| Interferon-α+lopinavir/ritonavir | 96 (24.43%) | 69 (17.47%) | 0.007 |
| Lopinavir/ritonavir+arbidol | 38 (9.67%) | 35 (8.86%) | 0.620 |
| Lopinavir/ritonavir | 35 (8.91%) | 33 (8.35%) | 0.702 |
| Other | 63 (16.03%) | 64 (16.20%) | 0.844 |
| Mechanical ventilation | 6 (1.53%) | 12 (3.04%) | 0.232 |
| Non-invasive | 5 (1.27%) | 2 (0.51%) | 0.286 |
| Invasive | 1 (0.25%) | 10 (2.53%) | 0.011 |
| CRRT | 0 (0.00%) | 0 (0.00%) | |
| ECMO | 0 (0.00%) | 0 (0.00%) | |
| Glucocorticoids | 56 (14.25%) | 44 (11.14%) | 0.200 |
| Maximum dosage (mg)* | 40 (40–80) | 40 (40–80) | 0.953 |
| IVIG | 35 (8.91%) | 27 (6.84%) | 0.293 |
| Admission to intensive care unit | 5 (1.27%) | 17 (4.30%) | 0.015 |
| Discharged from hospital | 210 (53.44%) | 112 (28.35%) | <0.001 |
*
Glucocorticoid dosages were converted into an equivalent of methylprednisolone. Data are presented as number (percentage) or median (interquartile range, IQR). CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; IVIG: intravenous immunoglobulin